A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337), a specific inhibitor of thymidylate synthase, was developed using protein structure-based drug design. Intravenously administered nolatrexed is active clinically. As oral b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362691/
https://www.ncbi.nlm.nih.gov/pubmed/10070890
http://dx.doi.org/10.1038/sj.bjc.6690146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362691/
https://www.ncbi.nlm.nih.gov/pubmed/10070890
http://dx.doi.org/10.1038/sj.bjc.6690146

Ejemplares similares